Subtype
Thyroid Gland Carcinoma
CI-CAN-00006937THCAExplore in graph →
96 active trials8 approved drugs53 evidence items
- NCIt
- C4815
- DOID
- 3963
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006937THCAExplore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03122496 | Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | completed | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT02418390 | The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma | completed | N/A | 101 | Seoul National University HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02938702 | Active Surveillance on Papillary Thyroid Microcarcinoma | active not recruiting | — | 1,211 | Seoul National University HospitalOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05247476 | Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. | unknown | Phase 4 | 50 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT02688608 | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | completed | Phase 2 | 6 | Saad A KhanOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03647657 | 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer | completed | Early Phase 1 | 8 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05191927 | A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma | completed | — | 1,200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT02178345 | Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer | completed | — | 123 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT02041260 | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | unknown | Phase 2 | 43 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | withdrawn | Phase 2 | 0 | Antonio FojoOTHER | 0 | Oct 13, 2021 | clinicaltrials |
| NCT02764554 | Post-Marketing Surveillance of Lenvima in Korean Patients | completed | — | 132 | Eisai Korea Inc.INDUSTRY | 1 | Oct 7, 2021 | clinicaltrials |
| NCT05052359 | Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours | completed | — | 37 | National University Health System, SingaporeOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03942380 | Cell-free Tumor DNA in Head and Neck Cancer Patients | unknown | N/A | 500 | Christian von BuchwaldOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Aug 13, 2021 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | terminated | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04916262 | Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer | unknown | — | 160 | Qianfoshan HospitalOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04760171 | Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis | unknown | — | 10 | The Leeds Teaching Hospitals NHS TrustOTHER | 0 | Feb 18, 2021 | clinicaltrials |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma | withdrawn | N/A | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03072160 | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT01774279 | interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)(iNATT) | unknown | — | 350 | Velindre NHS TrustOTHER_GOV | 2 | Jan 5, 2021 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02138214 | Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer | completed | Phase 2 | 117 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04664413 | Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma(ABOUT) | unknown | — | 300 | University of SalernoOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT04666103 | Function Integrity of Neck Anatomy in Thyroid Surgery | recruiting | N/A | 1,264 | Wuhan UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03845647 | Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma. | unknown | N/A | 50 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03643055 | 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer | unknown | — | 80 | University Medical Centre LjubljanaOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04594720 | Circulating Biomarkers to Identify Thyroid Cancer | completed | — | 100 | Chang Gung Memorial HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01441154 | Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment | completed | — | 16 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT00668811 | Sutent Adjunctive Treatment of Differentiated Thyroid Cancer(IIT Sutent) | completed | Phase 2 | 23 | Medstar Health Research InstituteOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500925 | The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience | completed | — | 301 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Aug 5, 2020 | clinicaltrials |
| NCT01788982 | Nintedanib(BIBF1120) in Thyroid Cancer | completed | Phase 2 | 100 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 31, 2020 | clinicaltrials |
| NCT02174679 | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04076514 | The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma(pCND) | unknown | — | 20 | Assiut UniversityOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02726503 | Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer(HOPE) | completed | Phase 2 | 39 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04424485 | Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy | unknown | N/A | 100 | Umraniye Education and Research HospitalOTHER_GOV | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04411290 | Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases | unknown | — | 200 | Umraniye Education and Research HospitalOTHER_GOV | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04396912 | Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort | unknown | — | 100 | Umraniye Education and Research HospitalOTHER_GOV | 1 | May 21, 2020 | clinicaltrials |
| NCT04336696 | Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0? | unknown | N/A | 199 | Bassem Mohamed SiedaOTHER_GOV | 1 | Apr 7, 2020 | clinicaltrials |
| NCT03211117 | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03246659 | Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC(GRAN-T-MTC) | completed | Phase 1 | 16 | Paola Anna ErbaOTHER | 5 | Mar 20, 2020 | clinicaltrials |
| NCT02658513 | Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer | completed | — | 35 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Mar 11, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2022source: clinicaltrials